CSIMarket
 
89bio Inc   (ETNB)
Other Ticker:  
 
 
Price: $12.6200 $1.15 10.026%
Day's High: $13.34 Week Perf: 14.42 %
Day's Low: $ 11.74 30 Day Perf: 27.47 %
Volume (M): 2,265 52 Wk High: $ 22.93
Volume (M$): $ 28,584 52 Wk Avg: $13.78
Open: $11.85 52 Wk Low: $6.58



 Market Capitalization (Millions $) 963
 Shares Outstanding (Millions) 76
 Employees 20
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -127
 Cash Flow (TTM) (Millions $) 180
 Capital Exp. (TTM) (Millions $) 0

89bio Inc
89bio Inc. is a clinical-stage biopharmaceutical company that develops therapies for the treatment of liver and cardio-metabolic diseases. It is headquartered in San Francisco, California, and was founded in 2018.

The companyes focus is on developing innovative therapies for nonalcoholic steatohepatitis (NASH) and other liver and cardio-metabolic diseases. NASH is a severe form of nonalcoholic fatty liver disease (NAFLD) that affects about 16 million people in the United States alone. It is characterized by the buildup of fat in the liver, inflammation, and damage to liver cells, which can lead to liver cirrhosis, liver failure, and liver cancer.

89bioes lead product candidate, called BIO89-100, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist designed to treat NASH. GLP-1 is a naturally occurring hormone that stimulates insulin secretion and reduces appetite. BIO89-100 is designed to improve insulin sensitivity, reduce liver fat, prevent liver inflammation, and improve liver fibrosis.

BIO89-100 has completed a Phase 1b/2a clinical trial in patients with NASH and demonstrated promising efficacy and safety results. The company plans to initiate a Phase 2b clinical trial in the second half of 202

Besides BIO89-100, 89bio has two other product candidates in its pipeline. These are BIO89-050 and BIO89-070, both of which are GLP-1 receptor agonists designed for the treatment of obesity and type 2 diabetes. These product candidates are in preclinical development.

89bio has a team of experienced executives and scientists with a track record of developing successful therapies for liver diseases. The company is backed by a group of leading biotechnology investors, including RA Capital, OrbiMed Advisors, Vivo Capital, Cormorant Asset Management, and Aju IB Investment.

In summary, 89bio is a clinical-stage biopharmaceutical company that develops innovative therapies for the treatment of liver and cardio-metabolic diseases, with a particular focus on NASH. Its lead product candidate, BIO89-100, has demonstrated promising efficacy and safety in a Phase 1b/2a clinical trial and is expected to enter a Phase 2b clinical trial in the second half of 202 The company also has two other product candidates in preclinical development for the treatment of obesity and type 2 diabetes.


   Company Address: 142 Sansome Street San Francisco 94104 CA
   Company Phone Number: 432-9270   Stock Exchange / Ticker: NASDAQ ETNB
   ETNB is expected to report next financial results on March 13, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Market Announcement

89bio Inc. Continues to Invest in Talent and Innovation Amidst Market Challenges

Published Mon, Feb 5 2024 9:05 PM UTC

In a recent announcement, 89bio, Inc. revealed that it has approved the grant of non-qualified stock options to two new employees as part of its ongoing efforts to attract top talent and drive growth in the development of innovative therapies for liver and cardiometabolic diseases. These inducement grants, totaling 28,400 shares of the company's common stock, were granted un...

Stock Market Announcement

89bio Inc. Raises $172.5 Million in Upsized Offering to Propel Development of Game-Changing Therapies for Liver and Cardiometabolic Diseases

Published Tue, Dec 12 2023 12:30 PM UTC



SAN FRANCISCO - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in the development and commercialization of advanced therapies for liver and cardiometabolic diseases, announced the successful closure of its substantially upsized underwritten public offering on December 12, 2023. The offering, which includes pre-funded warrants, g...

Shares

89bio, Inc. Seeks to Advance Liver and Cardiometabolic Therapies with Proposed Public Offering

Published Wed, Dec 6 2023 9:36 PM UTC


SAN FRANCISCO, Dec. 06, 2023 - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focusing on liver and cardiometabolic disease treatments, has announced its intention to conduct an underwritten public offering of common stock and pre-funded warrants. This offering aims to raise $125.0 million to further support the development and commercialization ...

Clinical Study

89bio Gains Regulatory Consent for Pegozafermin's Phase 3 Program in NASH, Accelerating Treatment Access for Severe Liver Disease Patients

Published Mon, Dec 4 2023 12:00 PM UTC



In a significant development for 89bio Inc, the biopharmaceutical company has successfully reached alignment with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the Phase 3 program for its novel drug candidate, Pegozafermin, for the treatment of Nonalcoholic Steatohepatitis (NASH). This alignment paves the way for the in...

Clinical Study

89bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, has recently announced new encouraging data from their ENLIVEN Phase 2b trial of pegozafermin The trial showed that the treatment led to sustained and significant improvements in NASH patients with fibrosis stage F2-F3 These positive long-term results are promising for patients suffering from this progressive and potentially life-threatening disease

Published Mon, Nov 27 2023 1:01 PM UTC

89bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, has recently announced new encouraging data from their ENLIVEN Phase 2b trial of pegozafermin. The trial showed that the treatment led to sustained and significant improvements in NASH patients with fibrosis stage F2-F3. These positive lon...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com